Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
StarkAge Therapeutics logo — Immunotherapy against senescence

StarkAge Therapeutics

Immunotherapy against senescence

Founded 2018 France France 11 employees Series Unknown Total: $3.20M Biotechnology

General Information

Company Name StarkAge Therapeutics
Founded Year 2018
Location France France +1
Employees 11
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when StarkAge Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About StarkAge Therapeutics

StarkAge Therapeutics, founded in 2018, is a biotechnology startup based in France with the slogan "Immunotherapy against senescence." The company aims to combat age-related diseases by targeting senescent cells accumulation. Utilizing its unique disease-specific exosomal/EV technology and leveraging immunotherapy, the company seeks to address the significant unmet medical needs associated with senescence. The most recent milestone for StarkAge Therapeutics is the €1.20M Venture Round investment received on 29 May 2024, with Bpifrance as the lead investor. This injection of funds underscores investor confidence in the potential of the startup's approach to revolutionize the treatment of age-related diseases through innovative technology and immunotherapy. Overall, StarkAge Therapeutics presents a compelling opportunity for venture capitalists looking to tap into the rapidly evolving landscape of biotechnology and immunotherapy. With its strategic focus on targeting senescence and improving the quality of life for patients, the startup shows promise in reshaping the future of disease management in the aging population.

Taxonomy: senescence, immunotherapy, exosomal technology, EV technology, senescent cells, age-related diseases, idiopathic pulmonary fibrosis, neurodegenerative diseases, metabolic dysfunction, hepatic fibroses, disease-specific, discovery-stage, therapeutics, medical needs

Services & Products

Development of targeted therapies for age-related diseases using monoclonal antibodies and biomarker discovery

Target Customers

Patients suffering from age-related diseases healthcare professionals research institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1
Investor
29 May 2024
Venture Round •••••• 1
Investor
20 Jan 2022

StarkAge Therapeutics Alternatives & Competitors

StarkAge Therapeutics vs
Aileron Therapeutics
Aileron Therapeutics United States

Developing novel medicines to provide better treatment options for patients with life-threatening pu...

Post Ipo Equity
17 employees
Biopharma, Biotechnology
StarkAge Therapeutics vs
Alentis Therapeutics
Alentis Therapeutics Switzerland

We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis

Series D
69 employees
Biotechnology, Health and Wellness
StarkAge Therapeutics vs
Tandem Therapeutics
Tandem Therapeutics Switzerland

Unlocking the matrix barrier to treat fibrotic diseases

Non Equity Assistance
5 employees
Health and Wellness

FAQ About StarkAge Therapeutics

Immunotherapy against senescence
StarkAge Therapeutics was founded in 2018.
StarkAge Therapeutics is headquartered in France.
StarkAge Therapeutics operates in the following industries: Biotechnology.
StarkAge Therapeutics has approximately 11 employees.
StarkAge Therapeutics has completed 2 funding rounds, raising a total of $3.20M. The latest funding stage is Series Unknown.
StarkAge Therapeutics offers: Development of targeted therapies for age-related diseases using monoclonal antibodies and biomarker discovery.
Top alternatives and competitors to StarkAge Therapeutics include Aileron Therapeutics, Alentis Therapeutics, Tandem Therapeutics, GRI Bio, Inc., Neupharma Srl. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
StarkAge Therapeutics and Aileron Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors StarkAge Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy